Volume 15 Issue 3

1 Haplotype analysis at R778L mutation of ATP7B gene in Korean patients with Wilson disease

Clin Mol Hepatol. 2009;15(3):295-298.

2 Molecular targeting for treatment of advanced hepatocellular carcinoma

Clin Mol Hepatol. 2009;15(3):299-308.

3s Haplotype analysis and possible founder effect at the R778L mutation of the ATP7B gene in Korean patients with Wilson`s disease

Clin Mol Hepatol. 2009;15(3):309-319.

Prognostic value of serum osteopontin in hepatocellular carcinoma patients treated with transarterial chemoembolization

Clin Mol Hepatol. 2009;15(3):320-330.

Efficacy of 48-week clevudine therapy for chronic hepatitis B

Clin Mol Hepatol. 2009;15(3):331-337.

Impact of adherence to peginterferon-ribavirin combination therapy in chronic hepatitis C patients on achieving a sustained virologic response

Clin Mol Hepatol. 2009;15(3):338-349.

Comparison of the Model for End-stage Liver Disease and hepatic venous pressure gradient for predicting survival in patients with decompensated Liver cirrhosis

Clin Mol Hepatol. 2009;15(3):350-356.

4s A case of metastatic hepatocellular carcinoma of the rib, treated by transcatheter arterial chemoembolization

Clin Mol Hepatol. 2009;15(3):357-361.

Four patients with hepatitis A presenting with fulminant hepatitis and acute renal failure and who underwent Liver transplantation

Clin Mol Hepatol. 2009;15(3):362-369.

A case of sudden-onset hearing Loss in a patient treated with peginterferon α-2b and ribavirin for chronic hepatitis C

Clin Mol Hepatol. 2009;15(3):370-374.

5 Large Liver cell change/dysplasia in hepatitis B virus-related Liver cirrhosis

Clin Mol Hepatol. 2009;15(3):375-378.

6 Peliosis hepatis

Clin Mol Hepatol. 2009;15(3):379-382.

7 The Korean Journal Of Clinical outcomes and development of hepatocellular carcinoma after HBsAg seroclearance in chronic hepatitis B patients

Clin Mol Hepatol. 2009;15(3):383-390.

11 Special Contribution : Practice guidelines for management of hepatocellular carcinoma 2009

Clin Mol Hepatol. 2009;15(3):391-423.